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Recent emphasis on translational research (TR) is highlighting the role of epidemiology in translating scientiﬁc
discoveries into population health impact. The authors present applications of epidemiology in TR through 4
phases designated T1–T4, illustrated by examples from human genomics. In T1, epidemiology explores the role
of a basic scientiﬁc discovery (e.g., a disease risk factor or biomarker) in developing a ‘‘candidate application’’ for
use in practice (e.g., a test used to guide interventions). In T2, epidemiology can help to evaluate the efﬁcacy of
a candidate application by using observational studies and randomized controlled trials. In T3, epidemiology can
help to assess facilitators and barriers for uptake and implementation of candidate applications in practice. In T4,
epidemiology can help to assess the impact of using candidate applications on population health outcomes.
Epidemiology also has a leading role in knowledge synthesis, especially using quantitative methods (e.g., meta-
analysis). To explore the emergence of TR in epidemiology, the authors compared articles published in selected
issues of the Journal in 1999 and 2009. The proportion of articles identiﬁed as translational doubled from 16%
(11/69) in 1999 to 33% (22/66) in 2009 (P ¼ 0.02). Epidemiology is increasingly recognized as an important
component of TR. By quantifying and integrating knowledge across disciplines, epidemiology provides crucial
methods and tools for TR.
epidemiology; genomics; medicine; public health; translational research
Abbreviations: HuGE, human genome epidemiology; HuGENet, Human Genome Epidemiology Network; TE, translational
epidemiology; TR, translational research.
Editor’s note: An invited commentary on this commentary
appears on page 525, and the authors’response is published
on page 528.
Translational research means different things to different
people, but it seems important to almost everyone.
S. H. Woolf (1, p. 211).
In a recent editorial launching the new journal Science
Translational Medicine, Dr. Elias Zerhouni, former director
of the National Institutes of Health, remarked that despite
decades of advances in our understanding of human biology
and the emergence of powerful new technologies, such as
genomics, the transformation of scientiﬁc discoveries into
effective health interventions continues to elude us (2).
There is daunting complexity when applying basic discov-
eries and experimental approaches to treating and prevent-
ing human disease, requiring a strong translational research
(TR) agenda. He stressed the need for ‘‘more and better TR,
both for the sake of our patients and because much of the
research funding ...comes from the primary expectation of
the public that such scientiﬁc investigations will reduce the
burden of disease’’ (2, p. 1). Translation of promising sci-
entiﬁc discoveries into day-to-day practice is slow and un-
certain (3), with only a few scientists willing to venture into
the translation gap, sometimes referred to as the ‘‘valley of
death’’ (4, p. 840). Perhaps no ﬁeld has generated higher
expectations, deeper frustrations, and more ‘‘translation
anxiety’’ than advances in human genomics. In 2003,
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Heart, Lung, and Blood Institute, remarked that the gap
between what we know about diseases and what we do to
prevent and treat them will likely grow wider as new tech-
nologies emerge, as there is plenty of evidence that even
established interventions have been ‘‘lost in translation’’
(5, p. 868). He asked, ‘‘Let’s be realistic: If we didn’t do
it with aspirin, how can we expect to do it with DNA?’’
(5, p. 874). In public health, even with decades-long knowl-
edge, cigarette smoking, physical inactivity, and poor diet
are the main contributors to the global burden of common
chronic diseases, such as diabetes and coronary heart dis-
ease. Yet, progress has been slow in translating this knowl-
edge into a reduction of the burden of these diseases (6).
This may be due to many forces other than the lack of data
and scientiﬁc evidence, including political, social, legal, and
economical. In this paper, we present a framework for
epidemiology as a fundamental building block of the TR
enterprise, using illustrations from the emerging ﬁeld of
human genomics. The emerging ﬁeld of genomics offers
a nice example, because it has the advantage of showing
the potential contribution of epidemiology to all phases of
TR. Moreover, it exempliﬁes the difﬁculties of translation
(despite high expectations) and the relatively steep decrease
in the number of studies as one moves from T1 to T4.
However, the framework can be applicable to all areas of
health besides genomics.
Although epidemiologic methods have helped to discover
the underlying causes of many human diseases, they may be
even more crucial for providing the data for translating these
discoveries into population health beneﬁts. We discuss
translational epidemiology (TE) along a multidisciplinary
research continuum (Table 1; Figure 1) and highlight the
function of knowledge synthesis at each stage. Over the past
few years, the term ‘‘translational research’’ has been used
in the context of clinical and other enterprises in the United
States and globally (7–9); however, to our knowledge, this is
the ﬁrst paper to present an inclusive perspective of TE. Our
Table 1. Epidemiology and the Phases of Translation and Knowledge Synthesis—From Discovery to Population Health Impact
Phase Details Role of Epidemiology Examples From Genomics
T0 Description and discovery Describing patterns of health
outcomes by place, time, and
person; ﬁnding determinants of
health outcomes by use of
observational studies
Describing patterns of health outcomes in
relation to inbreeding, migration, and family
history to generate hypotheses about
genetic factors; genome-wide association
studies as a tool for gene discovery
T1 From discovery to health applications
(tests, interventions)
Characterizing discovery and
assessing potential health
applications by using clinical
and population studies
Assessing prevalence, associations,
interactions, sensitivity, speciﬁcity, and
predictive value of testing for genetic risk
factors
T2 From health application to evidence
guidelines
Assessing the efﬁcacy of
interventions to improve health
and prevent disease by using
observational and experimental
studies
Assessing the clinical utility of genetic risk
factors in improving health outcomes
T3 From guidelines to health practice Assessing the implementation and
dissemination of guidelines into
practice
Assessing the factors associated with
implementation of BRCA testing in practice
T4 From health practice to population
health outcomes
Assessing the effectiveness of
interventions on health outcomes
Assessing the effectiveness of newborn
screening programs
Knowledge
synthesis
Systematic review of what we know
and what we do not know and how
we know it
Knowledge synthesis applies to all
phases of translation by use of
evidence synthesis and systematic
reviews.
T1—evaluating the credibility of genetic
associations and assessing the genetic
effects and interactions (through HuGENet)
T2—systematic reviews on the clinical validity
and utility of genomic applications for
speciﬁc intended uses (through EGAPP
appraisal)
Abbreviations: EGAPP, Evaluation of Genomic Applicationsin Practice and Prevention; HuGENet, Human GenomeEpidemiologyNetwork; T0–
T4, designated phases of translational research.
Scientific  
Discovery
Candidate
Application
Practice and
Control
Programs 
Population
Health–Disease
Burden
T1
Evidence-based
Recommendation 
or Policy
T2
T3
T4
Knowledge
Synthesis
T0
Figure 1. Epidemiology and the phases of translational research:
T0, scientiﬁc discovery research; T1, translational research from dis-
covery to candidate application; T2, translational research from can-
didate application to evidence-based recommendation or policy; T3,
translational research from recommendation to practice and control
programs; T4, translational research from practice to population
health impact.
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epidemiology to TR. We hope that the framework will sup-
port further discussion of the contributions of epidemiology
to translational research and spur the integration of epide-
miologic concepts into training curricula for clinical and
public health practice to meet the increasing challenge of
translating scientiﬁc discoveries into population health
beneﬁts.
THE CONTRIBUTION OF EPIDEMIOLOGY TO
SCIENTIFIC DISCOVERIES
The schema in Figure 1 combines both clinical and public
health approaches to translating scientiﬁc discoveries into
effective, evidence-based approaches to treatment, preven-
tion, and control of human disease in populations. A ‘‘sci-
entiﬁc discovery’’ (designated T0) refers to new knowledge
and insight into the causes, pathobiology, or natural history
of disease. T0 research can come from laboratory sciences,
as well as clinical and public health disciplines. In fact,
epidemiology has long had an important role in describing
disease occurrence in populations (descriptive epidemiol-
ogy) and understanding the determinants of such occurrence
(analytical or risk factor epidemiology). For example, epi-
demiologic studies helped to establish cigarette smoking as
a major risk factor for lung cancer and folic acid as pro-
tective against the occurrence of neural tube defects (10).
Because of the multilevel determinants of human disease
(from molecular to social and ecologic factors), team or
transdisciplinary science is increasingly recognized as the
key to new discoveries (6). As remarked recently by Bob
Hiatt, ‘‘...epidemiology has a central role in team science,
no matter what the health issue at hand’’ (11, p. 859). In
human genomics, consortia and networks have rapidly
emerged as important infrastructure for the discovery of
genetic risk factors for various common diseases, especially
for genome-wide association studies, which require very
large sample sizes for discovery and replication (12, 13).
TRANSLATIONAL RESEARCH: FROM SCIENTIFIC
DISCOVERY TO POPULATION HEALTH IMPACT
A central dilemma in medicine and public health is the
translation of basic discoveries into clinical practice and
population health. A familiar concept in TR refers to the
translation of basic laboratory discoveries to useful clinical
applications as ‘‘bench to bedside’’ research (1, p. 211; 11,
p. 859), as the ‘‘effective translation of the new knowledge,
mechanisms, and techniques generated by advances in basic
science research into new approaches for prevention, diag-
nosis, and treatment of disease’’ (1, p. 211). In 2006, the
National Institutes of Health launched the Clinical and
Translational Science Award program as a stimulus for
TR, which it deﬁned as ‘‘the process of applying discoveries
generated during research in the laboratory, and in preclin-
ical studies, to the development of trials and studies in
humans’’ (14). Many laboratory research scientists view
TR as a linear, unidirectional process for using laboratory
discoveries to develop therapeutics for study in human clin-
ical trials; however, even this form of TR is iterative, in-
cluding feedback loops from bedside to bench (15). These
concepts apply to the development of both therapeutic
agents and biomarkers that could be used for diagnosis
and early detection (e.g., prostate-speciﬁc antigen testing
for early detection of prostate cancer).
On the other hand, public health and health services
researchers tend to view TR as a process for developing
evidence-based interventions and implementing them in
practice, thus ‘‘ensuring that new treatments and research
knowledge actually reach the patients or populations for
whom they are intended and are implemented correctly’’
(1, p. 211). The production of a new drug, an end point
for ‘‘bench-to-bedside’’ TR, is only the starting point for
this second phase of translation. The Institute of Medicine’s
Clinical Research Roundtable (16) reconciled these 2 views
of TR by deﬁning 2 research gaps: T1 is ‘‘the transfer of new
understandings of disease mechanisms gained in the labo-
ratory into the development of new methods for diagnosis,
therapy, and prevention and their ﬁrst testing in humans’’
(16, p. 1279); and T2 is ‘‘the translation of results from
clinical studies into everyday clinical practice and health
decision making’’ (16, p. 1279). One example is the evi-
dence for whether or not prostate-speciﬁc antigen testing
can be proven to improve morbidity and mortality when
used in intervention trials.
Westfall et al. (17) proposed further dividing the second
phase of TR, deﬁning T2 as research to develop evidence-
based recommendations and policies and T3 as research on
implementing and disseminating evidence-based interven-
tions in practice. For example, in the case of prostate-speciﬁc
antigen, T2 would conduct trials to evaluate the beneﬁts and
harms of using prostate-speciﬁc antigen screening to detect
prostate cancer, while T3 would implement research to get
prostate-speciﬁc antigen screening in practice. Khoury et al.
(18)recentlyadaptedtheTRframeworktogenomicmedicine
and added a ﬁnal phase, T4, which focuses on evaluating the
population-level health impact ofinterventions. In the case of
prostate-speciﬁc antigen, T4 research would involve looking
at the health impact of prostate screening in unselected pop-
ulations (or real world practice). Figure 1 represents the re-
lations among the 4 phases of TR research, with knowledge
synthesis (discussed below) playing a central role. This
schema is consistent with the comprehensive view of TR,
which is not limited to drug development but includes behav-
ioral, social, and policy interventions to address individual or
collective determinants of health, recently published by Ogil-
vie et al. (19). It is noteworthy that Figure 1 depicts a logical
progression from T1 through T4 research. However, the pro-
cess is not necessarily linear. T3 and T4 research can be done
on a candidate application that is not used in practice even
before an evidence-based recommendation is made on its
appropriate use (refer to the example of personal genomics
tests below).
HOW DOES EPIDEMIOLOGY CONTRIBUTE TO
TRANSLATIONAL RESEARCH?
Using the proposed T1–T4 translational research frame-
work (Table 1; Figure 1), we examine the role of
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discoveries into clinical and public health applications. We
use the term ‘‘translational epidemiology’’ (TE) to describe
the application of epidemiologic methods in all phases of
TR (i.e., the study of disease distribution and determinants
in populations). TE overlaps with and encompasses such
terms as ‘‘applied epidemiology’’ (20), ‘‘clinical epidemi-
ology’’ (21), and ‘‘ﬁeld epidemiology’’ (22)—all referring
to post-discovery research butused invarious ways, depend-
ing on the context of applications of epidemiologic research,
according to the purpose of the research, the phase of its
application, and the determinants and outcomes of interest.
TE is at the intersection of clinical and population-based
research, including observational studies and randomized
controlled trials (sometimes called experimental epidemiol-
ogy) (23), assessing how basic discoveries can be used to
improve health.
T1 epidemiologic research assesses the potential of a dis-
covery for developing a ‘‘candidate application’’ for use in
clinical or public health practice. Candidate applications are
not limited to diagnostics or therapeutics; they can be con-
sidered more broadly to include behavioral, social, and pol-
icy interventions (e.g., tobacco regulations to help control
smoking-related morbidity and mortality; physical activity
to prevent type 2 diabetes).
In human genomics research, T1 epidemiologic research
is needed to replicate and characterize genetic associations
discovered by candidate gene studies and genome-wide as-
sociation studies (24). For example, characterizing the prev-
alence of genetic risk factors in different populations and
ethnic groups, assessing their contributions to disease bur-
den, and evaluating gene-gene and gene-environment inter-
actions are all questions requiring additional epidemiologic
research (25). The importance of T1 epidemiologic research
in human genomics cannot be underestimated. Recently,
several companies have begun marketing so-called personal
genomic tests directly to consumers; these tests are derived
from discovery research and are offered with the implicit
purpose of guiding health risk assessment and disease pre-
vention (26). However, many associations included in per-
sonal genomic tests have not been replicated (27), and the
risks calculated by different companies are often inconsis-
tent (28). Yang et al. (29) recently showed that, in general,
the estimated lifetime risks of disease include a large
amount of uncertainty depending on variation in disease
incidence rates, temporal trends, risk ratios, prevalence of
genetic risk factors, and interactions with other risk factors.
T1 epidemiologic research can begin to look beyond odds
ratios (30) to applied measures, such as the sensitivity, spec-
iﬁcity, and predictive value of genetic variants, singly or in
combination, in the context of other disease risk factors
(such as environmental exposures). For example, T1 epide-
miologic research in human genomics includes the analysis
of cohort studies to assess the value of adding genetic var-
iants to conventional risk prediction models for coronary
heart disease, some cancers, and type 2 diabetes (31). So
far, these studies have shown that genetic risk factors add
very little to the area under a receiver operating character-
istic curve generated by well-established disease prediction
algorithms (e.g., the Framingham score) (32).
T2 epidemiologic research is required to establish the
clinical utility of a candidate application, concluding with
a comprehensive assessment of the balance of beneﬁts and
harms of its use. Results of such research are the basis for
evidence-based recommendations by professional groups or
independent panels, such as the US Preventive Services
Task Force (33). T2 epidemiologic research includes both
observational studies and randomized controlled trials.
Although phase III randomized controlled trials are rou-
tinely conducted to evaluate new drugs, behavioral inter-
ventions are also amenable to these trials. For example,
the highly successful Diabetes Prevention Program re-
cruited individuals at high risk for type 2 diabetes and
randomized them prospectively to receive pharmacologic
and behavioral interventions, including diet and physical
activity (34).
In human genomics, T2 epidemiologic research assesses
the value of genomic information in directing primary
prevention, early detection, and treatment of disease (e.g.,
pharmacogenomics) (35). Principles of comparative effec-
tiveness research are the basis for comparing the results of
gene-directed interventions with those of standard interven-
tions (36). So far, very few genomic applications have been
evaluated for clinical utility (18, 37). In general, most dis-
covered common genetic variants have low clinical validity
and, furthermore, information from single or small sets of
genetic markers discovered in genome-wide association
studies is unlikely to have clinical utility (38). Even when
a strong genetic association exists (e.g., factor V Leiden
with recurrent venous thromboembolism), genetic testing
may not improve clinical outcomes (39). In general, few
randomized controlled trials have been conducted to evalu-
ate the clinical utility of genomic applications in practice.
One of the few examples of a genomic application evaluated
by an ongoing randomized controlled trial is the use of
breast cancer gene expression proﬁles to direct chemother-
apy to women at high risk of recurrence (40).
T3 epidemiologic research addresses the major challenge
of translating candidate applications into health-care practice
and disease prevention programs. The Institute of Medicine’s
report,CrossingtheQualityChasm:ANewHealthSystemfor
the 21st Century, summarized the difﬁculty of effective im-
plementation and diffusion of proven health-care interven-
tions (41). According to McGlynn et al. (42), patients in
the United States receive only half of the preventive services
for which evidence-based recommendations exist. The over-
use of inefﬁcient or potentially harmful interventions is also
an important concern (43). Discussing global health issues,
Madon et al. recently remarked that ‘‘many evidence-based
innovations fail to produce results when transferred to com-
munities, largely because their implementation is untested,
unsuitable, or incomplete’’ (44, p. 1728). Because health de-
livery schemes are difﬁcult to study with randomized con-
trolled trials, other epidemiologic approaches contribute to
the ‘‘implementation sciences’’ for assessing facilitators
and barriers to uptake and implementation of evidence-based
recommendations. ‘‘Why do established programs lose ef-
fectiveness over days, weeks, or months? Why do tested
programs sometimes exhibit unintended effects when trans-
ferred to a new setting? How can multiple interventions be
520 Khoury et al.
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the splintering of health systems into disease speciﬁc pro-
grams? Answering questions like these will require analysis
of biological, social, and environmental factors that impact
implementation’’ (44, p. 1728).
In human genomics, few applications are currently ready
for implementation in clinical practice. A notable exception
is the breast cancer susceptibility gene (BRCA) mutation
testing for assessing risk of breast and ovarian cancer. In
2005, the US Preventive Services Task Force issued an
evidence-based recommendation that ‘‘women whose fam-
ily history is associated with an increased risk for deleteri-
ous mutations in BRCA1 or BRCA2 genes should be referred
for genetic counseling and evaluation for BRCA testing’’
(45). Very few studies to date have evaluated the extent
and determinants of uptake of such recommendations in
various clinical and population settings. For the personal
genomic tests available (with no evidence-based recom-
mendations), Kolor et al. (46) recently reported on 2 epi-
demiologic surveys of the population and primary care
providers in the United States, and they have documented
that a substantial fraction of the population and providers
are aware of these tests.Determinantsof awarenessinclude
gender (female), age (older groups), education (higher ed-
ucation), and race (whites). Although only a small propor-
tion (0.3%) of respondents have used these tests, providers
are getting questions about such tests from their patients
and are likely to change some aspect of their practice as a
result of these tests, even without the requisite evidence
base around their use in practice. Simple T3 epidemiologic
data such as these help to document the mismatch between
scientiﬁc evidence and everyday practice, and they high-
light the need for more education and oversight of such
products (46).
T4 epidemiologic research evaluates the real world effec-
tiveness of a candidate application in terms of population-
level outcomes, such as morbidity, mortality, and disability,
at the population or health-care-system level. As Ogilvie
et al. (19) point out, the true end point of TR is not simply
institutionalizing effective interventions but improving pop-
ulation health. Established epidemiologic methods for sur-
veillance can be applied to risk factors (e.g., monitoring the
prevalence of obesity and cigarette smoking by using the
state-based Behavioral Risk Factor Surveillance System)
(47) or disease occurrence: For example, cancer surveil-
lance data have been used to model the impact of mammog-
raphy screening on breast cancer mortality (48). This view
of T4 research encompasses the whole spectrum of deter-
minants of health, from the individual to the collective level,
along with a corresponding spectrum of interventions.
In human genomics, very few applications have been
evaluated by T4 research. Perhaps the most notable example
is newborn screening for inherited metabolic disorders.
Although mandated public health newborn screening pro-
grams have been in place for decades, they have only
recently integrated new technologies (particularly tandem
mass spectrometry) for identifying an expanded number
of disorders (49). Surveillance and outcomes research are
being used to document the real world effectiveness and
potential harms of these new tests (50).
KNOWLEDGE SYNTHESIS: AN ENGINE FOR
TRANSLATIONAL EPIDEMIOLOGY
Knowledge synthesis is a systematic approach to review-
ing the evidenceon what we knowand whatwe do notknow,
and how we know it. We have indicated the essential role for
knowledge synthesis in all phases of TR by placing it at the
center of Figure 1. Knowledge synthesis methods, such as
meta-analysis, are becoming standard in developing
evidence-based recommendations forpractice (T2 research).
The Cochrane Collaboration (51), an international not-for-
proﬁt and independent organization founded in 1993,
produces and disseminates systematic reviews of health-care
interventions and promotes the search for evidence in the
form of clinical trials and other studies of interventions. It
continues to play a pivotal role in developing and promoting
quantitative synthesis of evidence of what works and what
does not work in health-care interventions. Increasingly,
other independent groups, such as the US Preventive Ser-
vices Task Force, are adopting similar methods (33, 52).
In human genomics, knowledge synthesis plays a key role
in T1 epidemiologic research. Since 1998, the Human
Genome Epidemiology Network (HuGENet) (53) has
sought to synthesize information on gene-disease associa-
tions through human genome epidemiology (HuGE) reviews
and meta-analyses. The Journal has been an active partner
Table 2. Articles in the American Journal of Epidemiology by
Translation Phase, 1999 and 2009
Issue and
Year
Descriptive/
Discovery
Epidemiology,
no.
Translational
Epidemiology, no.
Total,
no.
January 1
2009 9 3 (1 T1, 1 T4, 1 KS) 12
1999 18 2 (1 T1, 1 KS) 20
March 1
2009 8 5 (2 T1, 2 T4, 1 KS) 13
1999 9 1 (1 KS) 10
July 1
2009 10 4 (2 T1, 1 T4, 1 KS) 14
1999 10 3 (3 T1) 13
October 1
2009 10 4 (3 T1, 1 T4) 14
1999 11 2 (1 T1, 1 T4) 13
December 1
2009 7 6 (1 T1, 2 T4, 3 KS) 13
1999 10 3 (1 T1, 2 T4) 13
Total
2009 44 22 (9 T1, 7 T4, 6 KS)
a 66
1999 58 11 (6 T1, 3 T4, 2 KS)
b 69
Abbreviations: KS, knowledge synthesis; T0–T4, designated
phases of translational research.
a Examples of translational epidemiology in 2009 include T1
(reference 60), T4 (reference 61), and KS (reference 62).
b Examples of translational epidemiology in 1999 include T1
(reference 63), T4 (reference 64), and KS (reference 65).
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the past decade (54). HuGENet has also drafted guidelines
for assessing the credibility of genetic associations based on
the amount of evidence, the extent of replication, and the
degree of protection from bias (55). It has become the norm
for publications reporting a discovery from genome-wide
association studies to include a meta-analysis of replication
data sets (56, 57). As genomics research begins to yield
candidate applications for clinical and public health prac-
tice, knowledge synthesis will have an increasingly impor-
tant role in T2 research. For example, the Centers for
Disease Control and Prevention-supported initiative, Evalu-
ation of Genomic Applications in Practice and Prevention,
known as EGAPP, is a rigorous process for evaluating the
evidence on analytical and clinical validity and the clinical
utility of genomic applications for clinical and public health
practice in the United States (58, 59). An independent
EGAPP Working Group selects topics, oversees systematic
reviews of evidence, and makes evidence-based recommen-
dations; 5 systematic reviews and 4 evidence recommenda-
tions had been published by 2009 (58).
TRANSLATIONAL EPIDEMIOLOGY IN THE AMERICAN
JOURNAL OF EPIDEMIOLOGY
Finally, we thought it would be instructive to describe the
trends and types of translational research articles published in
the Journal as a snapshot of the ﬁeld. Although analysis of
any one journal is not necessarily generalizable to the whole
ﬁeld, we were curious to see how much scientiﬁc discovery
and translational research are published in a premier epide-
miology journal. We compared the contents of 5 issues of the
American Journal of Epidemiology published in 2009 with
the corresponding issues published in 1999. We read the titles
and abstracts of all the articles and classiﬁed them according
to our TE framework, from T0 through T4 and knowledge
synthesis. We assessed all the papers in each selected issue
and used a simple classiﬁcation of the article by purpose of
the study. We applied the deﬁnitions of T0–T4 described in
Table 1. If a paper addressed multiple phases of translation,
we coded the highest phase of translation. For illustration,
Table 2 shows examples (60–65) of each type of paper in
1999 and in 2009. The proportion of articles that could be
classiﬁed as TE increased from 16% (11/69) in 1999 to 33%
(22/66) in 2009 (P ¼ 0.02 by chi-square test; Table 2). Al-
though this exercise is by no means an exhaustive or repre-
sentative analysis of the epidemiology literature, it suggests
a positive trend. We are planning additional analyses of the
published literature in epidemiology, and clinical and public
health journals could help to clarify the trends in translational
research and the contributions of epidemiology to the ﬁeld. It
is possible that each journal has its own preferred niche in the
T1–T4 continuum, and an evaluation of many journals could
give a wider perspective about the interface of translational
research and epidemiology.
CONCLUDING REMARKS
In summary, we have presented a framework for epide-
miology as a fundamental science for translating basic dis-
coveries into population health beneﬁts. The TE framework
combines clinical and public health approaches to disease
treatment, prevention, and control. In combination with ba-
sic, clinical, and other population sciences, TE provides the
key data needed to document what we know and what we do
not know, and what works and what does not work, thus
inﬂuencing further research, practice, and policy develop-
ment. The framework encompasses previously described
areas of epidemiology, such as clinical and applied epide-
miology, and uniﬁes various concepts according to the pur-
pose of the research, the phase of its application, and the
determinants and outcomes of interest. We hope this frame-
work supports further discussion of the ﬁeld’s potential con-
tributions to translational research and spurs the continued
integration of epidemiologic concepts into training curricula
for clinical and public health practice. Finally,it isimportant
to acknowledge that actual translation is much more com-
plicated as different forces—such as private investments in
research and development, policy and legal frameworks,
oversight and regulation, product marketing, coverage and
reimbursements, consumer advocacy, provider awareness,
and consumer access—can accelerate or impede the trans-
lation process. These factors can often operate indepen-
dently from research evidence as we recently explored in
genomic medicine (66). Nevertheless, TE is a necessary in-
gredient to move speciﬁc discoveries from research into
practice in an evidence-based fashion. In an era of health
reform and comparative effectiveness research, epidemio-
logic data are fundamental to informed decision-making by
health-care providers, policy makers, and citizens.
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